Trial description:
A Phase 2-3, multicenter, randomized, doubleblind study of selinexor (KPT-330) versus placebo in patients with advanced unresectable dedifferentiated liposarcoma (DDLS)
Contact name:
Dr Helen Hatcher
Trial start date:
Wednesday, November 7, 2018
Trial end date:
Monday, August 31, 2020
Trial tumour type:
Sarcoma
Show on Radiotherapy:
No